All In Biotech

Drug Trial Radar · NCT07551492

A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 In Participants With Atherosclerotic Cardiovascular Disease

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Participants With Atherosclerotic Cardiovascular Disease (ASCVD)

Last checked: Nov 19, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 9,262 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

9,262

Planned (sponsor's estimate)

Start

May 29, 2026

Primary completion

May 24, 2031

Study completion Jun 28, 2031

Sponsor

Sponsor type
Industry
First posted
Apr 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the impact of HRS9531 on major adverse cardiovascular events (MACE) in patients with atherosclerotic cardiovascular disease. This study adopts an event-driven design and ends when the target number of the primary endpoint event is reached.

Conditions

  • Atherosclerotic Cardiovascular Disease

Interventions

  • HRS9531Drug

    HRS9531 Dose 1 , subcutaneous injection

  • HRS9531 placeboDrug

    HRS9531 placebo Dose 1, subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The time from randomization to the first occurrence of the MACE-3 composite endpointTime frame: approximately up to 61 months of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fuwai Hospital, CAMS&PUMC

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.